C. McCoy

发表

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials

A. Yang, C. Britten, B. George, 2022, Cytotherapy.

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

M. Rothenberg, A. Sandler, A. Schott, 2008, Clinical Cancer Research.

Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).

R. Plummer, J. Graham, B. Wiedenmann, 2008, European journal of cancer.

Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors.

R. Plummer, J. Graham, B. Wiedenmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose-escalation study of ZK 304709, an oral multi-target tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle.

W. Steward, R. Molife, M. Barrett, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

C. Redfern, E. Small, D. Guhathakurta, 2015, Clinical Cancer Research.

A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

C. Redfern, E. Small, N. Dawson, 2013 .

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

F. Marincola, L. Butterfield, P. Srivastava, 2012, Journal of Translational Medicine.

Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts).

P. Kantoff, M. Cooperberg, A. Armstrong, 2013 .

Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).

A. Kibel, C. Drake, N. Sheikh, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

W. Steward, J. Bono, P. Fong, 2009, Cancer Chemotherapy and Pharmacology.

Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors.

S. Eckhardt, L. Gore, M. Basche, 2004, Journal of Clinical Oncology.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

M. Fishman, N. Shore, S. Finkelstein, 2013, Cancer control : journal of the Moffitt Cancer Center.

A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.

A. Kibel, C. Drake, E. Antonarakis, 2013 .

Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors

S. Eckhardt, L. Gore, M. Basche, 2004 .

A Phase 1 dose escalation study of the pharmacokinetics and tolerability of ZK 304709 , an oral multi-targeted growth inhibitor ( MTGI TM ) , in patients with advanced solid tumours

Herbert, Wiesinger, W. Steward, 2009 .

Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.

E. Plimack, P. Sharma, D. Bajorin, 2014 .

Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: data from PROCEED.

M. Cooperberg, A. Armstrong, C. Higano, 2014, Clinical advances in hematology & oncology : H&O.

MP70-02 TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED

M. Cooperberg, A. Armstrong, C. Higano, 2013 .

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

M. Fishman, N. Shore, S. Finkelstein, 2013, Cancer control : journal of the Moffitt Cancer Center.

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

C. Redfern, E. Small, L. Fong, 2015, Clinical Cancer Research.